Published in Scientific Works. C Series. Veterinary Medicine, Vol. LVIII ISSUE 4
Written by Ilea Ioana Cristina, Pall Emoke, Ciupe Simona, Cenariu M., Roxana Roman, I.S.Groza
Mesenchymal stem cells (MSCs) are playing an important role in tissue engineering. Because of their properties to differentiate in multiple lineages, these cells became promising materials for the treatment of different types of degenerative disease, including bone disorders. In order to evaluate the distribution of xenogeneic MSCs engraftment, the aim of our study was the screening of human CD44+ MSCs distribution after intraperitoneal transplantation in a mouse model for osteoporosis. Human MSCs were harvested from the palatal subepithelial connective tissue. The cells were grown in DMEM/F12 (Sigma Aldrich) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml streptomycin. After i.p. transplantation of 1,1x106 CD44+ hMSCs in a mouse model, the screening of donor cells engraftment from blood samples was assessed at 4 and 11 days post-transplantation. The mice were euthanized by cervical dislocation at 14 days, followed by human MSCs engraftment assessment in blood, bone marrow and spleen samples. Results were quantified by immunophenotypic characterization with FACS Canto II flow cytometry system (BD Biosciences, San Jose, CA, USA). Our data confirmed the special homing characteristic of human MSCs in a mouse xenograft model. At 4 days post injection, in blood samples was found a percentage of 0,5% CD44+ cells and at 11 days, a percentage of 0,1% of CD44+ cells. At 14 days, a percentage of 0,1 % CD44+ human MSCs was found in blood as well as in bone marrow, but all spleen samples were negative.
[Read full article] [Citation]
engraftment
